Oncospire Genomics: CGI’s Joint-Venture with Mayo Clinic
In May 2013, CGI and Mayo Clinic agreed to form Oncospire Genomics (“Oncospire”) as an equally owned joint venture.
Oncospire works to devlop novel, next-generation sequencing (NGS) based diagnostic panels that provide clinically relevant and actionable insights in areas of critical need in oncology. The joint-venture will initially pursue the development of NGS panels for lung cancer, multiple myeloma, and follicular lymphoma.
LUNG CANCER With over 1.6 million new cases diagnosed annually, lung cancer is a category where earlier diagnosis and differentiation is critical to improved patient outcomes. To date, only a handful of biomarkers for lung cancer have been identified, and they do not fully address the need for diagnostic and predictive information.
MULTIPLE MYELOMA There are approximately 200,000 new cases of multiple myeloma diagnosed annually, and no comprehensive genomic panel that can be utilized to predict early transformation from monoclonal gammopathy of undetermined significance (“MGUS”) to multiple myeloma. Currently available tests are expensive, invasive, and often require multiple biopsies.
FOLLICULAR LYMPHOMA represents approximately 30% of all non-Hodgkin lymphomas, and is the second most common lymphoma in the U.S. We believe predicting the risk progression of follicular lymphoma is a key unmet clinical need, with a potential market of up to 45,000 tests annually based on disease prevalence and number of biopsies performed.